A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2996

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Placebo-matching dapagliflozin

Sponsor

AstraZeneca

Collaborators

[object Object]